Extensive hands-on experience of medical technology and building successful companies
Johan de Ruiter
Johan is founder of Auxilium Gruppe GmbH (orthopedics, rehab and homecare), Germany and LabNet AG (medical labs, now part of Amedes Holding) and Business Angel at Brains-to-Ventures AG, Switzerland, focusing on medical technology and health care services. Johan served as Executive Vice President Dialysis International of Fresenius AG where he was the initiator and a founding member of Fresenius Medical Care AG which is listed on the Frankfurt and New York Stock Exchanges. He was instrumental in moving the business from being the fourth largest global dialysis company to being the undisputed global leader in dialysis products and services. Prior to joining FMC he had sales and marketing management positions with Dade Diagnostics, a division of American Hospital Supply (Baxter), Abbott Diagnostics and Audi AG. He also was a manager with A.T.Kearney, Management Consultants and Associate Partner with Booz & Company. In addition to his Chairmanship of Quanta, Johan is Chairman of CHT/BEZEMA Group, a specialty chemical company, and a Non-Executive Director of GNA Biosolutions GmbH, a developer of molecular pathogen detection instruments.
John E. Milad
CEO & Founder
John is CEO of Quanta Dialysis Technologies, where he was both a founding board member and an original investor through NBGI Ventures. He had the belief and vision that the initial technology concept of a novel fluid management system could be transformed into a disruptive medical product addressing the unmet needs of the $73 billion global dialysis market by using innovation to empower patients and deliver better outcomes.
John’s career spans more than twenty years, with extensive international experience in building and growing successful healthcare companies as an executive manager, board member, private equity investor and corporate financier. He is currently an Advisory Board member of Digital Health Forum and is a regular speaker and panellist at global medtech and investment conferences. Prior to his role as CEO of Quanta, John was Investment Director at NBGI Ventures, where he was closely involved with a range of innovative medical technology companies in Europe and the US, both as a board member and an investor. John has also held senior positions at Nitec Pharma AG (now Horizon Pharma plc), Atlas Venture and Nomura international and previously served as a member of the i4i selection panel at the NHS National Institute for Health Research. John has also served on the Board of Directors at Cellnovo Ltd, Symetis SA, BoneSupport AB and Advanced Cardiac Therapeutics Inc. He holds a BA in Political Science from The University of Chicago.
Aris Constantinides is the Founder and an Investment Director of London-based NBGI Ventures, a fund with €100M under management. Aris has backed companies at all stages of development from raw start-ups to growth companies, and currently serves on the board of a number of US and European companies, both public and private, including: Advanced Cardiac Therapeutics, Cellnovo, Dysis Medical, EOS Imaging (NYSE Euronext: EOSI), Reverse Medical and Supersonic Imagine. Aris has been previously a board member of 2010/Technolas Perfect Vision (acquired by Bausch and Lomb), Direct Energie (acquired by Quilvest), Estech (acquired by Atricure) and InternetQ (LON:INTQ).
He has more than 16 years’ venture capital and private equity experience, previously with funds at Deutsche Bank and Credit Suisse First Boston. Aris started his career at Bankers Trust, where he structured innovative derivative products. He holds Mechanical Engineering degrees from Imperial College (B.Eng) and the Massachusetts Institute of Technology (MS), as well as an MBA from INSEAD. Aris speaks fluent English, French, Greek and business-level Spanish.
Peter is Co-founder and Managing Partner of Seroba Life Sciences Limited and was a co-founder of Seroba Bioventures. He has held many directorships in the fund management, technology and financial services industries.
Peter was previously the Managing Director of ABN Amro Corporate Finance (Ireland) Limited where he had responsibility for the firm’s capital markets and venture capital businesses. Prior to joining ABN Amro, Peter worked in Corporate Advisory Services for Ernst & Young (E&Y) in London and Dublin, and during this period, Peter was also seconded to the Dublin office of 3i venture capital. Before that, he worked for KPMG. Peter has a BBS degree from Trinity College Dublin and is a Chartered Accountant. He was formerly a member of The Securities Institute, a Registered Stockbroker and a member of The Institute of Taxation in Ireland. Peter is on the committee of the Irish Venture Capital Association and was formerly a member of the Irish Stock Exchange’s New Issues Committee.
With over 20 investments in start-up companies, Rainer is one of Europe’s most experienced venture capitalists in Life Sciences. Joining Wellington Partners in 1997, he became a Partner in December 2000. His years of investment activity involved financing of some of the most successful European biotech companies. Prior to joining Wellington Partners, Rainer was involved in medical research with a primary focus on cardiovascular physiology and in research on health economics at Ludwig-Maximilians University in Munich. Rainer studied medicine and economics and holds a doctorate in medicine as well as a master’s degree in economics.
Marc David is the Investment Director of ALIAD Venture Capital, the investment arm of Air Liquide, which was created in late 2012. Marc joined Air Liquide in 1993 after previously working for a few years within an SME. He has held various positions including Corporate On-Site Engineering Deputy Director and Head of Corporate R&D within the core technologies and energy department. Marc also holds a PhD in Physics.
Giles Kerr has a successful commercial and financial track record with specific healthcare experience and a broad skill set covering all aspects of financial management. Giles has held a number of directorships, and is currently Director of Finance at Oxford University and serves on the board of BTG plc where he is also Chairman of the Audit Committee and Senior Independent Director. He also serves on the Board and as Chairman of the Audit Committee of both Senior plc and Victrex plc. In addition to this, Giles also serves as Non-Executive Director at ISIS Innovation Limited and Oxford Sciences Innovation plc.
Prior to his current roles, Giles served as Non-Executive Director at Elan Corporation Inc, was Chief Financial Officer of Amersham plc, which was acquired by GE Healthcare in 2004 and was a partner with Arthur Andersen in the UK. Giles graduated from the University of York, is a Fellow of the Institute of Chartered Accountants in England and Wales and a Fellow of Keble College , Oxford.
Dr Francesco Granata
Dr Francesco Granata is an accomplished healthcare executive with over 35 years’ experience in the biopharmaceutical and medical products industries; currently serving as chairman of Circassia as well as also serving on the board of both Italfarmaco SpA and Prismic Pharmaceuticals Inc.
Prior to this, Dr Granata has held roles as Executive Vice President at Biogen Idec Inc and Group Vice President for Canada and Europe at Schering-Plough Corporation. Francesco further has held senior roles at Pfizer, Pharmacia & Upjohn and Glaxo Smith Kline. Dr Granata practiced as a Medical Doctor, specialising in cardiology, and has a Doctorate of Medicine and Surgery from the University of Pavia, Italy.
Christian Schütz is a Partner at btov and is responsible for Life Science and Cleantech investments. Since starting in 2003, he has managed over 20 investments in start-up companies and is a member of the btov Board of Directors and the General Partners of both btov Funds. Christian studied international business administration, holds a master’s degree and earned a PhD in Banking and Entrepreneurial Finance from the European Business School (ebs), Oestrich-Winkel.